PTH1R Inhibitors
2 drugsAbout PTH1R
The parathyroid hormone 1 receptor (PTH1R) is a GPCR crucial for calcium homeostasis, activated by parathyroid hormone (PTH) and PTHrP. This activation triggers signaling pathways regulating bone remodeling, kidney function, and calcium levels.
PTH1R's established physiological function makes it a valuable drug target, though no genetic evidence directly links it to specific diseases. Therapeutics address conditions where calcium regulation is disrupted.
PTH1R is targeted by two FDA-approved peptide drugs: YORVIPATH and TYMLOS. These drugs are developed by ASCENDIS PHARMA BONE and RADIUS, respectively, for other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Malaria with only 1 trials.
Top Drugs
The PTH1R competitive landscape includes ASCENDIS PHARMA BONE and RADIUS, each with an approved drug.
Low market concentration suggests opportunities for new entrants, but high barriers to entry due to established players.
Drug Modality Landscape
Modalities
Routes of Administration
PTH1R is primarily targeted by peptide modalities (100% of approved drugs).
Explore non-peptide modalities to differentiate from existing therapies and expand market reach.
Clinical Trials 95 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 15 | 0 | 1 | 100% |
| Phase 2 | 31 | 23 | 7 | 1 | 77% |
| Phase 3 | 18 | 17 | 1 | 0 | 94% |
| Phase 4 | 30 | 21 | 2 | 4 | 91% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (2017 - 2024)
The first PTH1R drug was approved in 2017 (TYMLOS), with the most recent approval in 2024 (YORVIPATH).
Recent approval indicates continued interest, but monitor for market saturation as the field matures.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 30 clinical trials targeting PTH1R.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities